期刊
AMERICAN JOURNAL OF TRANSPLANTATION
卷 23, 期 10, 页码 1603-1611出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/j.ajt.2023.05.032
关键词
CD2/CD58; CD28/B7; siplizumab; belatacept; abatacept; mixed lymphocyte reaction
Combined therapy of siplizumab with abatacept or belatacept can effectively suppress T cell proliferation, enhance siplizumab-mediated T cell inhibition, and improve the selective depletion of memory T cells. This combination therapy may be used for the prophylaxis of organ transplant rejection and improvement of long-term outcomes following transplantation.
Combined antigen-specific T cell receptor stimulation and costimulation are needed for complete T cell activation. Belatacept and abatacept are nondepleting fusion proteins blocking CD28/B7 costimulation, whereas siplizumab is a depleting antiCD2 immunoglobulin G1 monoclonal antibody targeting CD2/CD58 costimulation. Herein, the effect of siplizumab combination therapy with abatacept or belatacept on T cell alloreactivity in mixed lymphocyte reactions was investigated. In contrast to monotherapy, the combination of siplizumab with belatacept or abatacept induced near-complete suppression of T cell proliferation and increased the potency of siplizumab-mediated T cell inhibition. Furthermore, dual targeting of CD2 and CD28 costimulation enhanced the selective depletion of memory T cells compared with monotherapy. Although siplizumab monotherapy leads to significant regulatory T cell enrichment, high doses of cytotoxic T-lymphocyte-associated antigen 4 and a human IgG1 Fc fragment in the combination therapy reduced this effect. These results support the clinical evaluation of dual costimulation blockade, combining siplizumab with abatacept or belatacept, for the prophylaxis of organ transplant rejection and improvement of long-term outcomes following transplantation. Ongoing investigative research will elucidate when other forms of siplizumab-based dual costimulatory blockade may be able to induce similarly strong inhibition of T cell activation although still allowing for enrichment of regulatory T cells.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据